← Issue №4/ week of Jul 26, 2026/Hepatology

Long-term follow-up, complications and outcomes of Meso-Rex bypass for extrahepatic portal vein obstruction (EHPVO): a systematic review.

From GI Signals issue №4: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Hepatology meta analysis · Jul 27, 2026 · Dig Liver Dis · IF 4.2

Long-term follow-up, complications and outcomes of Meso-Rex bypass for extrahepatic portal vein obstruction (EHPVO): a systematic review.

New evidenceportal hypertensionvariceal bleedingpediatricsystematic review
Clinical takeawayConsider Meso-Rex bypass for pediatric EHPVO patients with portal hypertension complications (GI bleeding, hypersplenism, thrombocytopenia) when standard medical therapy (NSBB, EVL) fails, given its high patency and low mortality but acknowledging thrombosis/stenosis risks and persistent portal hypertension.
What it foundMeso-Rex bypass achieved shunt patency in 87% (1229/1403) of pediatric EHPVO cases, with thrombosis in 9%, stenosis in 5%, recurrent GI bleeding in 13% (92/730), and 0.3% mortality (5 deaths, 1 MRB-related). Portal pressures decreased postoperatively but remained above 10 mmHg.
ContextConfirms MRB as a durable, effective surgical option for pediatric EHPVO, with consistent improvements in hematologic parameters and portal hypertension complications, though long-term follow-up protocols remain unstandardized.
Measured against the standard of care· AASLD/EASL/APASL/ALEH multisociety consensus 2026 (diagnosis) / AASLD 2021 vascular liver disorders guidance (management)

Decision at stakechoosing a definitive treatment for pediatric extrahepatic portal vein obstruction (EHPVO)

… Specific signs of portal hypertension are variceal bleeding, medium or large esophageal varices, gastric varices, spontaneous portosystemic shunts, spleen stiffness above 40 kPa without an MPN, and HVPG or porto-caval gradient of 10 mmHg or more. … Manage portal hypertension complications as in cirrhosis: NSBB (carvedilol preferred) or EVL for variceal prophylaxis, and TIPS for refractory or recurrent bleeding. …

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Diagnosis now follows the 2026 multisociety consensus (AASLD, EASL, APASL and ALEH, with the pathology and pediatric societies ESP, Hans Popper, SGIHPBPs, NASPGHAN and ESPGHAN). PSVD and NCPF are interchangeable names for one clinicopathological diagnosis. A liver biopsy is mandatory, and it must exclude cirrhosis. A specimen of at least 15 mm with at least one fragment of 10 mm or more is enough to do that. The listed alternative conditions must also be excluded. Signs of portal hypertension are no longer required for the diagnosis. PSVD/NCPF can coexist with another chronic liver disease as long as the biopsy shows no cirrhosis. Major histology is any of: NRH, muscularized portal venules, or portal venule stenosis in at least 50% of portal tracts. Minor histology is any of: regenerative changes without NRH, abnormal distribution of vascular structures, or portal venule stenosis in 25-49% of portal tracts. All three minor criteria together count as one major criterion. Specific signs of portal hypertension are variceal bleeding, medium or large esophageal varices, gastric varices, spontaneous portosystemic shunts, spleen stiffness above 40 kPa without an MPN, and HVPG or porto-caval gradient of 10 mmHg or more. Non-specific signs are clinical ascites, small varices, platelets below 150 G/L and splenomegaly. Scoring takes only the highest item in each domain. Portal hypertension scores 0 if absent, 2 if only non-specific signs, 3 if any specific sign. Histology scores 0 if normal, 2 for up to two minor criteria, 5 for any major criterion or all three minor. An associated condition adds 1. A concomitant cause of cirrhosis subtracts 1; metabolic syndrome without biopsy-proven MASLD does not count. A total of 2 or less means the diagnosis cannot be made, 3-4 is possible PSVD/NCPF (follow up and/or refer to an expert center), and 5 or more is confirmed. Low liver stiffness with high spleen stiffness, MRI periportal hyperintensity, or a nodular surface with a normal or enlarged segment IV add suspicion but no points. Three former exclusions were dropped. An intrahepatic portal cavernoma no longer excludes the diagnosis. SOS diagnosed more than 6 months earlier after stem cell transplant no longer excludes it. In endemic areas without hepatosplenic schistosomiasis, positive schistosomal serology or a few eggs on biopsy no longer exclude it. The consensus does not cover management, so management is unchanged from AASLD 2021. Look for associated conditions and causes: drugs, MPN, thrombophilia, PNH, autoimmune disease, CVID, HIV. Manage portal hypertension complications as in cirrhosis: NSBB (carvedilol preferred) or EVL for variceal prophylaxis, and TIPS for refractory or recurrent bleeding. Stop offending drugs and treat the specific cause. Decide on anticoagulation for coexisting PVT case by case, weighing thrombus acuity, bleeding risk and cause. Reserve liver transplant for refractory complications. HCC surveillance is not routine without cirrhosis.

AASLD/EASL/APASL/ALEH multisociety consensus 2026 (diagnosis) / AASLD 2021 vascular liver disorders guidance (management) · reviewed 2026-10-25 ↗
Riva P … Guérin F · Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · IF 4.2 · PubMed ↗Permalink
← Read the whole of issue №4 Every paper GI Signals surfaces gets a page like this one. All issues